Navigation Links
PBS-Bio works with 3 new firms to accelerate cancer drug development
Date:10/20/2010

tural control over cancer cell growth."

Although initially focused on lung and pancreatic cancer, Yarger said, "Our data supports the notion that NDC-1308 may control the growth of many kinds of aggressively growing cancers. We hope to further verify this data with PBS-Bio's technology."

Revalesio

Revalesio is targeting inflammation associated with various inflammatory mediated diseases, including cancer, through the creation of charged-stabilized nanostructures, or CSNs.

CSNs are aqueous based nano-bubble cores surrounded by an ionic scaffolding stabilized with free energy. CSNs interact with cells, specifically nave immune cells, altering the surface of the cell membrane and preventing unwanted downstream cellular activity that causes inflammation.

"We're developing a new technology that has novel anti-inflammatory effects applicable to a broad range of diseases," said Dr. Richard Watson, Director of Revalesio's Clinical Science. This technology is under development for the treatment of asthma, cardiovascular disease, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and other inflammatory mediated diseases.

"The charged-stabilized nanostructure is a platform from which we can create a variety of products as combination therapies or standalone therapeutics," Dr. Watson said. "Working with PBS-Bio, we want to see how our technology alters cell-survival in a number of different cancer lines, specifically looking at the connection of specific signaling pathways to inflammatory processes and proliferation signaling in oncology."

Unibioscreen

At hospitals in Belgium and the Netherlands, Unibioscreen has begun phase 1 clinical trials first in human tests with a drug called UNBS1450.

The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of an African plant called Calotropis procera. Pre-clinical tests have shown t
'/>"/>

Contact: Dr. Edward Smith
edsmith@pbs-bio.com
602-418-9300
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Report: Discovery networks hostage-taking a rare terror event
2. University of Miami to host prestigious National Geographic Young Explorers Workshop, Sept. 25
3. IU receives $9.2 million from NSF to expand global networks and research
4. SRNL works to decrease hazards from mold in water damaged homes
5. Wildlife, virus zoonoses focus of workshop
6. Plastic antibody works in first tests in living animals
7. Moral issues raised by synthetic biology subject of Hastings Center workshop
8. AAPS presents therapeutic protein drug interactions workshop
9. Entertainment Studios Networks Names Janice Arouh President, Domestic Distribution and Marketing
10. Modeling reef ecosystems focus of workshop
11. Forest service co-hosts annual air pollution workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
... release is available in German . ... have now developed a new strategy for the formation ... have thus been able to fuse the specific biological ... properties of plastics. Polymer-protein hybrid materials may be of ...
... with a particularly aggressive form of breast cancer seem ... combined anthracycline and taxane chemotherapy regimen before surgery, together ... results from the largest multi-centre trial to investigate this ... Breast Cancer Conference (EBCC-6) in Berlin today (Friday) that ...
... Alliance for Lupus Research (ALR) recently announced it will award ... ALR is very proud to announce, during National Minority Health ... has funded more than 100 research projects, and committed more ... says ALR President Barbara Boyts. For a full list of ...
Cached Biology News:Green gel 2Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer 2The Alliance for Lupus Research announces 2008 grantees 2
(Date:9/2/2015)... , Sept. 2, 2015 ... announced the addition of Jain PharmaBiotech,s new ... to their offering. ... pharmaceutical and biotechnology industries is anticipated. Nanotechnology ... drug development - from formulations for optimal ...
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... Israel , September 2, 2015 ... announced the intent of the National Institute of Allergy and ... Health (NIH) within the Department of Health and Human Services ... held in the United States in ... BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a primer ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... WILMINGTON, Delaware, November 3 The new market ... (2009 - 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) ... market. It identifies and analyzes,the main market drivers, ... and applications submarkets in different,geographic regions. , ...
... ... key hire. Cindy Larkin has been hired as Director of Client Services. Cindy ... , ... (Vocus) November 3, 2009 -- Leading medical device and life sciences software engineering consulting ...
... of Delaware has won a $4.4 million grant ... Projects Agency (ARPA-E) to lead a multidisciplinary, multi-institutional ... high-performance permanent magnets. Stronger magnets are essential ... information technology, and communications systems in the 21st-century, ...
Cached Biology Technology:MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2UD wins $4.4 million to develop next-generation magnets 2
pH-insensitive fluorescence (pH 2-12)...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Biology Products: